Dina Titus sold AstraZeneca PLC (NASDAQ: AZN)
Dina Titus (D-NV), a U.S. Representative, has disclosed 1 trade in AstraZeneca PLC (AZN) since 2016, a single sale, worth an estimated $8K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a sale: Dina Titus sold $1,001 - $15,000 of AstraZeneca PLC (NASDAQ: AZN) on November 21, 2016. Since that trade, AZN is up +356.91% against the S&P 500 up +297.60%, an outperformance of +59.32%.
Data updated
Dina Titus's AZN trades vs the price
AZN is up +356.91% since Dina Titus sold on November 21, 2016, versus +297.60% for the S&P 500.
Performance since this trade
All Dina Titus AZN trades
Dina Titus & AZN trading FAQ
Is it legal for Dina Titus to trade AstraZeneca PLC (AZN) stock?
Yes. Members of Congress are allowed to trade individual stocks, including AstraZeneca PLC (AZN), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. BullishWhales tracks those disclosures; this page does not imply the trade was improper.
When did Dina Titus sell AZN?
Dina Titus disclosed a sale of $1,001 - $15,000 of AstraZeneca PLC (AZN) on November 21, 2016, according to public STOCK Act filings.
How has AZN performed since Dina Titus's trade?
Since Dina Titus sold AZN on November 21, 2016, the stock is up +356.91%, versus +297.60% for the S&P 500 over the same period, an outperformance of +59.32%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional AZN trades?
BullishWhales tracks every disclosed congressional trade in AstraZeneca PLC (AZN) on the AstraZeneca PLC congressional trading page, which aggregates filings across all members of Congress.
Dina Titus's AZN tradesAll congressional filings for AstraZeneca PLCDina Titus's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.